We are live on !
Find out more
Birchview Capital Portfolio holdings
AUM
$173M
Turnover
41.05%
1-Year Est. Return
89.27%
This Fund
S&P 500
This Quarter Est. Return
-16.77%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$140M
AUM Growth
-$33.4M
(-19%)
Cap. Flow
+$24.5K
Cap. Flow % of AUM
Cap. Flow %
0.02%
Top 10 Holdings %
Top 10 Hldgs %
90.94%
Holding
43
New
3
Increased
9
Reduced
4
Closed
3
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Collegium Pharmaceutical
COLL
|
+$327K |
| 2 |
Accelerate Diagnostics
AXDX
|
+$282K |
| 3 |
CELG
Celgene
CELG
|
+$278K |
| 4 |
Pacific Biosciences
PACB
|
+$266K |
| 5 |
OXFD
Oxford Immunotec Global
OXFD
|
+$164K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
Medivation
MDVN
|
+$508K |
| 2 |
PTC Therapeutics
PTCT
|
+$483K |
| 3 |
Gilead Sciences
GILD
|
+$387K |
| 4 |
Cerus
CERS
|
+$313K |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$221K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.79% |
| 2 | Energy | 3.24% |
| 3 | Consumer Staples | 2.76% |
| 4 | Miscellaneous | 2.08% |
| 5 | Technology | 0.12% |
Similar funds
AMAL
6SA
Birchview Capital's Q1 2016 Portfolio in Review
As of Q1 2016, Birchview Capital held 43 positions worth $140M, down 19% from $174M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Birchview Capital's Q1 2016 filing shows 3 new, 9 increased, 4 reduced and 3 closed positions. Its largest new stake was Pacific Biosciences: 27,000 shares worth $230K. The largest sale was Medivation, an estimated $508K.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.
- Birchview Capital's largest Q1 2016 buy was Pacific Biosciences: 27,000 shares worth $230K.
- Birchview Capital added most to Collegium Pharmaceutical in Q1 2016, an estimated $327K increase.
- Birchview Capital's biggest Q1 2016 reduction was Medivation, cutting an estimated $508K.
- Birchview Capital fully exited PTC Therapeutics in Q1 2016, selling an estimated $483K.
- Birchview Capital's ten largest holdings make up 91% of its $140M portfolio in Q1 2016.
- Birchview Capital opened 3 new positions and closed 3 in Q1 2016.
- Birchview Capital's portfolio value fell 19% quarter-over-quarter to $140M.
Based on Birchview Capital's 13F filing for Q1 2016, filed 28 Apr 2016.